Boehringer Ingelheim International GmbH

General information

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein, Rhineland-Palatinate
Germany

Contact person: Scott DeWire, Head of Global Business Development
Company main phone: +49 (6132) 770
Company main fax: +49 (6132) 720
Website: https://www.boehringer-ingelheim.com

Year founded:	1885
Source of foundation:	Independent foundation
Name of foundation source:	Founded by Mr. Albert Boehringer
No. of employees:	Worldwide: 54500

Corporate description / mission:
Boehringer Ingelheim International GmbH is a company focused on developing and manufacturing medicines for human and animal health. Its Human Pharma business focuses on therapeutic areas including cardiovascular and metabolic diseases, oncology, respiratory diseases, immunology, mental health and retinal diseases, while its Animal Health business develops vaccines, therapeutics and parasite-control products for pets, horses and livestock. The company also provides biopharmaceutical development and manufacturing services for its own products and external customers through its BioXcellence business.

State of ownership: Private / independent
Headquarters: HQ: Yes

Remarks on ownership / listings
Boehringer Ingelheim GmbH was formerly known as Boehringer Ingelheim Zentrale GmbH and changed its name to Boehringer Ingelheim GmbH in 1989.

Categorization

Sector:

Pharma (fully integrated)

Subsector:

Anti-infectives
Antibodies
Gene therapy
Nucleic acid drugs
Peptides
Proteins
Vaccines

Primary therapeutic areas:

Cardiovascular / cardiology
Digestive system / gastroenterology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the eye / ophthalmology
Diseases of the nervous system / neurology
Endocrine, nutritional and metabolic diseases / endocrinology
External causes of morbidity and mortality / traumatology
Genitourinary system / Urology
Infectious and parasitic diseases / infectiology / parasitology
Mental and behavioural disorders / psychiatry /psychology
Musculoskeletal system and connective tissue / Orthopedics
Neoplasms / cancer / oncology
Respiratory / pulmonology
Skin and subcutaneous tissue / dermatology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

In-licensing
Manufacturer
Out-licensing
R&D
Supplier / Distributor

Customer segments:

Hospitals
Large biotech & big pharma
Physicians / doctors
Small biotech

Distribution:

Direct (own sales force)
Indirect (independent dealer)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	43
Phase I:	43
Phase II:	25
Phase III:	14
On the market:	23

Description of products:
Survodutide
Spesolimab, etc.

Collaborations & Clients

Partnering strategy / collaborations:
Re-Vana Therapeutics
Institute of Molecular Pathology (IMP)
Institute of Molecular Biology (IMB)
University of Applied Sciences in Biberach, Germany
University of Ulm, Germany
Technische Universität Dresden, etc.